In a filing, Qiagen NV revealed its Officer Sackers Roland acquired Company’s shares for reported $1.15 million on Sep 11 ’24. In the deal valued at $46.00 per share,25,000 shares were bought.
Redburn Atlantic downgraded its Qiagen NV [QGEN] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who decreased its forecast for the stock in mid February from “an Outperform” to “a Neutral”. Morgan Stanley also remained covering QGEN and has decreased its forecast on January 06, 2025 with a “an Equal-weight” recommendation from previously “an Overweight” rating. Jefferies revised its rating on December 10, 2024. It rated QGEN as “a Buy” which previously was an “a Hold”.
Price Performance Review of QGEN
On Monday, Qiagen NV [NYSE:QGEN] saw its stock jump 2.63% to $42.96. Over the last five days, the stock has gained 0.35%. Qiagen NV shares have fallen nearly -3.51% since the year began. Nevertheless, the stocks have risen 0.06% over the past one year. While a 52-week high of $47.92 was reached on 01/22/25, a 52-week low of $37.63 was recorded on 03/04/25. SMA at 50 days reached $40.64, while 200 days put it at $43.95.
Levels Of Support And Resistance For QGEN Stock
The 24-hour chart illustrates a support level at 42.30, which if violated will result in even more drops to 41.63. On the upside, there is a resistance level at 43.30. A further resistance level may holdings at 43.63. The Relative Strength Index (RSI) on the 14-day chart is 56.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 28.90%. Stochastics %K at 49.26% indicates the stock is a holding.
